Cargando…

Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy

BACKGROUND: Aberrant expression of the RON receptor tyrosine kinase is a pathogenic feature and a validated drug target in various types of cancers. Currently, therapeutic antibodies targeting RON for cancer therapy are under intensive evaluation. Here we report the development and validation of a n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Hang-Ping, Feng, Liang, Suthe, Sreedhar Reddy, Chen, Ling-Hui, Weng, Tian-Hao, Hu, Chen-Yu, Jun, Eun Sung, Wu, Zhi-Gang, Wang, Wei-Lin, Kim, Song Cheol, Tong, Xiang-Min, Wang, Ming-Hai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419354/ https://www.ncbi.nlm.nih.gov/pubmed/30871619 http://dx.doi.org/10.1186/s40425-019-0525-0

Ejemplares similares

Correction to: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
por: Yao, Hang-Ping, et al.
Publicado: (2019)

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials
por: Yao, Hang-Ping, et al.
Publicado: (2020)

The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells
por: Yao, Hang-Ping, et al.
Publicado: (2011)

Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy
por: Tong, Xiang-Min, et al.
Publicado: (2019)

Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis
por: Chen, Jun-Feng, et al.
Publicado: (2017)

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy
por: Yao, Hang-Ping, et al.
Publicado: (2020)

Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160
por: Lu, Yi, et al.
Publicado: (2008)

Bivalent EGFR-Targeting DARPin-MMAE Conjugates
por: Karsten, Lennard, et al.
Publicado: (2022)

Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain
por: Wang, Xin, et al.
Publicado: (2014)

Guanidine-modified albumin-MMAE conjugates with enhanced endocytosis ability
por: Yi, Ce, et al.
Publicado: (2023)

An Introduction and Overview of RON Receptor Tyrosine Kinase Signaling
por: Hunt, Brian G., et al.
Publicado: (2023)

Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction
por: Wang, Ming-Hai, et al.
Publicado: (2013)

Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)
por: Chang, Hsuan Ping, et al.
Publicado: (2021)

Regulation of Macrophage Polarization by RON Receptor Tyrosine Kinase Signaling
por: Chaudhuri, Amitabha
Publicado: (2014)

RON tyrosine kinase mutations in brain metastases from lung cancer
por: Milan, Melissa, et al.
Publicado: (2018)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
por: Hu, Chen-Yu, et al.
Publicado: (2019)

Crystal Structure of the Sema-PSI Extracellular Domain of Human RON Receptor Tyrosine Kinase
por: Chao, Kinlin L., et al.
Publicado: (2012)

Enzyme-linked immunosorbent assays for quantification of MMAE-conjugated ADCs and total antibodies in cynomolgus monkey sera
por: Pei, Min, et al.
Publicado: (2022)

Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy
por: Wang, Yanming, et al.
Publicado: (2019)

Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenografts
por: Koga, Yoshikatsu, et al.
Publicado: (2015)

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer
por: Weng, Tian-Hao, et al.
Publicado: (2020)

The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma
por: Berning, Philipp, et al.
Publicado: (2020)

MicroRNA Expression Profiling of Lung Cancer with Differential Expression of the RON Receptor Tyrosine Kinase
por: Ou, Huilin, et al.
Publicado: (2021)

Variant RONΔ160 of the RON receptor tyrosine kinase promotes the growth and invasion in vitro and in vivo in gastric cancer cell lines
por: Zhou, Dong-Hui, et al.
Publicado: (2015)

The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies
por: Cazes, Alex, et al.
Publicado: (2022)

ZT Optimization: An Application Focus
por: Tuley, Richard, et al.
Publicado: (2017)

Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety
por: Wang, Yanming, et al.
Publicado: (2020)

Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2(V617F) against myeloproliferative neoplasms
por: Hu, Min, et al.
Publicado: (2019)

Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues
por: Zhou, Donghui, et al.
Publicado: (2008)

THE RON RECEPTOR TYROSINE KINASE POSITIVELY REGULATES ANGIOGENIC CHEMOKINE PRODUCTION IN PROSTATE CANCER CELLS
por: Thobe, Megan N., et al.
Publicado: (2009)

Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer
por: Batth, Izhar Singh, et al.
Publicado: (2021)

Old Drug, New Delivery Strategy: MMAE Repackaged
por: Lahnif, Hanane, et al.
Publicado: (2023)

Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase
por: Ma, Qi, et al.
Publicado: (2010)

Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies
por: Li, Chunze, et al.
Publicado: (2019)

An EGFR‐targeting antibody–drug conjugate LR004‐VC‐MMAE: potential in esophageal squamous cell carcinoma and other malignancies
por: Hu, Xin‐yue, et al.
Publicado: (2018)

The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells
por: Feres, K.J., et al.
Publicado: (2008)

Neuroprotective Role of the Ron Receptor Tyrosine Kinase Underlying Central Nervous System Inflammation in Health and Disease
por: Dey, Adwitia, et al.
Publicado: (2018)

The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming
por: Cunha, Stéphanie, et al.
Publicado: (2014)

Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer
por: Zheng, Chao, et al.
Publicado: (2023)

Optimizing thermocouple’s ZT through design innovation
por: Zhang, Tinggang
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9ljk9hvjjar41r1dn02g3vp125